Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Nov 22, 2022 10:08am
191 Views
Post# 35118465

RE:RE:RE:RE:RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET

RE:RE:RE:RE:RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ETTwo definite angles at play here (IMO):

1.  reduce the risk with OTENA and bring as much on the acute/chronic side to market over time.
          - this will add to our desirability in partnering deals for OTENA
          - strike early with a less important geography (e.g. Japan)
          - better financial deal if a smaller geography joins earlier.
          - would put some good cash in the bank and negate any concerns of doing P3 alone (strategy)

2.  IBD to be the next potential blockbuster in the queue (still waiting for Q4 update)
          - this may add to future desirability for acquisition discussions
          - watch for the antiviral and the IBD drug to both be key components of an auto-immune angle

All riding on a smooth outcome for P2-Bunionectomy (new formulation key to risk reduction - 2-4 fold reduction in dosing)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities